Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 39, Issue 3, 2000, Pages 292-299

  Sallee, Floyd R ^a   Kurlan, Roger ^b   Goetz, Christopher G ^c   Singer, Harvey ^d   Scahill, Lawrence ^e   Law, Gordon ^g   Dittman, Valerie M ^g   Chappell, Phillip B ^f,g  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Department of Nursing ^*

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antipsychotic agents; Tics; Tourette's syndrome; Ziprasidone

Indexed keywords

PLACEBO; ZIPRASIDONE;

ADOLESCENT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GILLES DE LA TOURETTE SYNDROME; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SOMNOLENCE; TARDIVE DYSKINESIA; VIDEORECORDING;

EID: 0034093224     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004583-200003000-00010     Document Type: Article

References (37)

1. American Psychiatric Association (1994), Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington, DC: American Psychiatric Association
2. Bhadrinath BR (1998), Olanzapine in Tourette syndrome (letter). Br J Psychiatry 172:366
3. Braude WM, Barnes TR, Gore SM (1983), Clinical characteristics of akathisia: a systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 143:139-150
4. Bruun RD, Budman CL (1996), Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry 57:29-31
5. Caine ED, Polinsky RJ, Kartzinel R, Ebert MH (1979),The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 136:317-320
6. Chappell PB, Riddle MA, Scahill L et al. (1995), Guanfacine treatment of comorbid attention deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 34:1140-1146
7. Chappell PB, Scahill LD, Leckman JF (1997), Future therapies of Tourette syndrome. Neurol Clin North Am 15:429-450
8. Coffey BJ, Miguel EC, Savage CR, Rauch SL (1997), Tourette's disorder and related problems: a review and update. Harv Rev Psychiatry 2:121-132
9. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M and the Ziprasidone Study Group (1999), Ziprasidone 80 mg/day and 160 mg/day in die acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 20:491-505
10. Frantz AG, Wilson JD (1985), Endocrine disorders of the breast. In: Textbook of Endocrinology, Wilson JD, Foster DW, eds. Philadelphia: Saunders, pp 402-412
11. Gerlach J, Peacock L (1995), New antipsychotics: the present status. Int Clin Psychopharmacol 10(suppl 3):39-48
12. Goetz CG (1992), Clonidine and clonazepam in Tourette syndrome. Adv Neurol 58:245-251
13. Goetz CG, Tanner CM, Wilson RS, Shannon KM (1987), A rating scale for Gilles de la Tourette's syndrome: description, reliability and treatment. Neurology 37:1542-1544
14. Goff DC, Posever T, Herz L et al. (1998), An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 18:296-304
15. Kompoliti K, Goetz C (1997), Clinical rating and quantitative assessment of tics. Neural Clin North Am 15:239-254
16. Krishnamoorthy J, King BH (1998), Open-label olanzapine treatment in five preadolescent children. J Child Adolesc Psychopharmacol 8:107-113
17. Leckman JF, Hardin MT, Riddle MA, Stevenson J, Ort SI, Cohen DJ (1991a), Clonidine treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 48:324-328
18. Leckman JF, Knorr AM, Rasmusson AM, Cohen DJ (1991b), Basal ganglia research and Tourette's syndromes (letter). Trends Neurosci 14:94
19. Leckman JF, Riddle MA, Hardin MT et al. (1989), The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 28:566-573
20. Leckman JF, Towbin KE, Ort SI, Cohen DJ (1988), Clinical assessment of tic disorder severity. In: Tourette's Syndrome and Tic Disorders: Clinical Understanding and Treatment, Cohen DJ, Bruun RD, Leckman DJ, eds. New York: Wiley, pp 56-58
21. Lombroso PJ, Scahill L, King TA et al. (1995), Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry 34:1147-1152
22. National Institute of Mental Health (1976), Abnormal movement scale. In: Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology, Guy W, ed. Rockville, MD: National Institute of Mental Health
23. Rapoport JL, Swedo SE, Leonard HL (1992), Childhood obsessive compulsive disorder. J Clin Psychiatry 53(suppl): 11-16
24. Sadovnick D, Kurlan R (1997),The increasingly complex genetics of Tourette's syndrome. Neurology 48:801-802
25. Sallee FR, Nesbitt L, Jackson C, Sine L, Sethuraman G (1997), Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry 154:1057-1062
26. Scahill L, Riddle MA, McSwiggan-Hardin M et al. (1997), Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 36:844-852
27. Seeger TF, Seymour PA, Schmidt AW et al. (1995), Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275:101-113
28. Silva RR, Munoz DM, Daniel W, Barickman J, Friedhoff AJ (1996), Causes of discontinuation in patients with Tourette's disorder: management and alternatives. J Clin Psychiatry 57:129-135
29. Simpson GM, Angus JWS (1970), A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212(suppl):11-19
30. Singer HS (1997), Neurobiology of Tourette syndrome. Neural Clin 15:357-379
31. Tourette Syndrome Study Group (1999), Short-term versus longer term pimozide therapy in Tourette's syndrome: a preliminary study. Neurology 52:874-877
32. US Food and Drug Administration, Center for Drug Administration and Research (1993), "COSTART" Coding Symbols for Thesaurus of Adverse Reaction Terms, 4th ed. Rockville, MD: US Food and Drug Administration
33. Van der Linden C, Bruggeman R, Van Woerkom T (1994), Serotonindopamine antagonist and Gilles de la Tourette's syndrome: an open pilot dose-titration study with risperidone (letter). Mov Disord 9:687-688
34. Walkup JT (1999), The psychiatry of Tourette syndrome. CNS Spectr 4:54-61
35. Walkup JT, Scahill LD, Riddle MA (1995), Disruptive behavior, hyperactivity, and learning disabilities in children with Tourette's syndrome. Adv Neural 65:259-272
36. Wirshing DA, Wirshing WC, Kysar L et al. (1999), Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60:358-363
37. Zorn SH, Lebel LL, Schmidt AW et al. (1999), Pharmacological and neurochemical studies with the new antipsychotic ziprasidone. In: Interactive Monoaminergic Basis of Brain Disorders, Palomo T, Beninger R, Archer T, eds. Madrid: Editorial Sintesis, pp 377-393